Skin spray for early-stage mycosis fungoides
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a spray solution applied to skin lesions caused by mycosis fungoides, a type of cutaneous T cell lymphoma. It aims to see how the spray affects bacteria on the skin and whether it helps the lesions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage mycosis fungoides (stage IA or IB).
- You have at least two skin lesions that have been present for at least 3 weeks and are at least 10 cm² in size.
- A swab test from one lesion shows a certain bacteria (staphylococcus aureus) but not severe enough to need antibiotics.
- You agree not to wash or apply topical products to the target lesions starting the night before each study visit.
- You agree to avoid using bleach or vinegar baths, or other antiseptics on the lesions during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special skin care body wash can improve skin lesions in people with mycosis fungoides, a type of skin lymphoma. Researchers will look at skin bacteria before and after using the wash.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This trial tests a gel form of a drug called duvelisib that you apply directly to skin lesions. It is for people with early-stage mycosis fungoides and may help control the patches without needing whole-body treatments.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This trial tests a low-dose radiation treatment to the skin for early-stage mycosis fungoides, a type of lymphoma that affects the skin. The goal is to see if this treatment can help eliminate the cancer cells.
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.